As of today (2025-05-05), the Forward Annual Dividend Yield of Mind Medicine is 0.00%.
As of today (2025-05-05), the Trailing Annual Dividend Yield of Mind Medicine is 0.00%.
MNMD's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.535 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Mind Medicine's Forward Dividend Yield %
For the Biotechnology subindustry, Mind Medicine's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mind Medicine's Forward Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mind Medicine's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Mind Medicine's Forward Dividend Yield % falls into.
Mind Medicine Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Mind Medicine (NAS:MNMD) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Mind Medicine Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Mind Medicine's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNMD has been successfully added to your